154
Participants
Start Date
January 11, 2019
Primary Completion Date
November 27, 2020
Study Completion Date
January 14, 2022
APR-246 + azacitidine
"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
Azacitidine
"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
Cornell Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Moffitt Cancer Center, Tampa
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Fred Hutchinson Cancer Research Center, Seattle
University of Pennsylvania, Abramson Cancer Center, Philadelphia
Johns Hopkins Medical Center, Baltimore
IUCT Oncopole, Toulouse
Mayo Clinic Jacksonville, Jacksonville
Memorial Health Care System South Florida, Hollywood
Vanderbilt University Medical Center, Nashville
CHU Nantes, Nantes
Cleveland Clinic, Cleveland
University of Iowa Hospitals and Clinics, Holden Cancer Center, Iowa City
Mayo Clinic Rochester, Rochester
Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago
University Of Chicago Medicine, Chicago
Washington University St. Louis, St Louis
Ochsner Cancer Institute, New Orleans
Hôpital Saint-Louis, Paris
MD Anderson Cancer Center, Houston
City of Hope, Duarte
Stanford University Cancer Research Center, Palo Alto
Yale Cancer Center, New Haven
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
CHU Nice, Nice
Lead Sponsor
Aprea Therapeutics
INDUSTRY